Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Carcinogenesis ; 34(10): 2409-14, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23722652

ABSTRACT

Peutz-Jeghers patients develop hamartomatous polyps and carcinomas of the gastrointestinal tract. Cyclooxygenase-2 accelerates polyp growth in Lkb1 (+/-) mice modelling Peutz-Jeghers polyposis. In this study, we aimed to evaluate the effect of the mutagenic carcinogen N-methylnitrosourea (MNU) on gastrointestinal tumourigenesis in Lkb1 (+/-) mice and to investigate the role of cyclooxygenase-2 on the tumourigenesis. We treated 40 Lkb1 (+/-) and 51 wild-type mice with MNU, 10 mice from both groups received the cyclooxygenase-2 inhibitor celecoxib. Carcinogen-treated Lkb1 (+/-) mice displayed worse survival (60%) than treated wild-type (100%, P = 0.028) or untreated Lkb1 (+/-) mice (92%, P = 0.045). Also, the gastrointestinal tumour burden was almost 10-fold higher in carcinogen-treated (2181 mm(3)) than in untreated (237 mm(3), P = 0.00045) Lkb1 (+/-) mice. Celecoxib was much less efficient in reducing tumourigenesis in MNU-treated mice (by 23%; 1686 mm(3)) than in untreated mice (76%; 58 mm(3)). Surprisingly, the increase in tumour burden in MNU-treated mice was not accompanied by consistent histological changes, with only a single focus of epithelial dysplasia noted. This study suggests that MNU promotes Peutz-Jeghers polyposis independently from the acceleration by cyclooxygenase-2.


Subject(s)
Carcinogenesis/drug effects , Carcinogenesis/genetics , Carcinogens/toxicity , Methylnitrosourea/toxicity , Peutz-Jeghers Syndrome/genetics , Peutz-Jeghers Syndrome/pathology , Protein Serine-Threonine Kinases/genetics , AMP-Activated Protein Kinases , Animals , Carcinogens/administration & dosage , Celecoxib , Cyclooxygenase 2 Inhibitors/pharmacology , Disease Models, Animal , Female , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Gastrointestinal Neoplasms/chemically induced , Gastrointestinal Neoplasms/genetics , Gastrointestinal Neoplasms/pathology , Methylnitrosourea/administration & dosage , Mice , Mice, Knockout , Peutz-Jeghers Syndrome/mortality , Pyrazoles/pharmacology , Sulfonamides/pharmacology
2.
Fam Cancer ; 10(3): 425-35, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21519908

ABSTRACT

The Peutz-Jeghers syndrome (PJS) culprit kinase LKB1 phosphorylates and activates multiple intracellular kinases regulating cell metabolism and polarity. The relevance of each of these pathways is highly variable depending on the tissue type, but typically represents functions of differentiated cells. These include formation and maintenance of specialized cell compartments in nerve axons, swift refunneling of metabolites and restructuring of cell architecture in response to environmental cues in committed lymphocytes, and ensuring energy-efficient oxygen-based energy expenditure. Such features are often lost or reduced in cancer cells, and indeed LKB1 defects in PJS-associated and sporadic cancers and even the benign PJS polyps lead to differentiation defects, including expansion of partially differentiated epithelial cells in PJS polyps and epithelial-to-mesenchymal transition in carcinomas. This review focuses on the involvement of LKB1 in the differentiation of epithelial, mesenchymal, hematopoietic and germinal lineages.


Subject(s)
Cell Differentiation , Peutz-Jeghers Syndrome/metabolism , Peutz-Jeghers Syndrome/pathology , Protein Serine-Threonine Kinases/metabolism , AMP-Activated Protein Kinase Kinases , Cell Polarity , Humans
3.
Am J Pathol ; 176(5): 2467-76, 2010 May.
Article in English | MEDLINE | ID: mdl-20363912

ABSTRACT

Gastrointestinal hamartomatous polyps in the Peutz-Jeghers cancer predisposition syndrome and its mouse model (Lkb1(+/-)) are presumed to contain all cell types native to the site of their occurrence. This study aimed to explore the pathogenesis of Peutz-Jeghers syndrome polyposis by characterizing cell types and differentiation of the epithelium of gastric polyps and predisposed mucosa. Both antral and fundic polyps were characterized by a deficit of pepsinogen C-expressing differentiated gland cells (antral gland, mucopeptic, and chief cells); in large fundic polyps, parietal cells were also absent. Gland cell loss was associated with an increase in precursor neck cells, an expansion of the proliferative zone, and an increase in smooth muscle alpha-actin expressing myofibroblasts in the polyp stroma. Lack of pepsinogen C-positive gland cells identified incipient polyps, and even the unaffected mucosa of young predisposed mice displayed an increase in pepsinogen C negative glands (25%; P = 0045). In addition, in small intestinal polyps, gland cell differentiation was defective, with the absence of Paneth cells. There were no signs of metaplastic differentiation in any of the tissues studied, and both the gastric and small intestinal defects were seen in Lkb1(+/-) mice, as well as polyps from patients with Peutz-Jeghers syndrome. These results identify impaired epithelial differentiation as the earliest pathological sign likely to contribute to tumorigenesis in individuals with inherited Lkb1 mutations.


Subject(s)
Gastric Mucosa/pathology , Mutation , Peutz-Jeghers Syndrome/metabolism , Animals , Cell Differentiation , Cell Proliferation , Humans , Immunohistochemistry , Intestinal Polyps/pathology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Models, Anatomic , Oligonucleotide Array Sequence Analysis , Pepsinogen C/chemistry
4.
Biochim Biophys Acta ; 1775(1): 63-75, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17010524

ABSTRACT

Inactivating germline mutations in the LKB1 gene underlie Peutz-Jeghers syndrome characterized by hamartomatous polyps and an elevated risk for cancer. Recent studies suggest the involvement of LKB1 also in more common human disorders including diabetes and in a significant fraction of lung adenocarcinomas. These observations have increased the interest towards signaling pathways of this tumor suppressor kinase. The recent breakthroughs in understanding the molecular functions of the LKB1 indicate its contribution as a regulator of cell polarity, energy metabolism and cell proliferation. Here we review how the substrates and cellular functions of LKB1 may be linked to Peutz-Jeghers syndrome and other diseases, and discuss how some of the molecular changes associated with altered LKB1 signaling might be used in therapeutic approaches.


Subject(s)
Protein Serine-Threonine Kinases/physiology , Tumor Suppressor Proteins/physiology , AMP-Activated Protein Kinase Kinases , Adenocarcinoma/genetics , Animals , Cell Polarity/physiology , Cell Proliferation/drug effects , Cyclooxygenase 2 Inhibitors/therapeutic use , Humans , Lung Neoplasms/genetics , Mice , Peutz-Jeghers Syndrome/genetics , Peutz-Jeghers Syndrome/physiopathology , Peutz-Jeghers Syndrome/therapy , Protein Kinases/physiology , Signal Transduction
5.
Medicine (Baltimore) ; 84(1): 35-47, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15643298

ABSTRACT

Acute intermittent porphyria (AIP), resulting from a deficiency of porphobilinogen deaminase (PBGD) in heme biosynthesis, is genetically heterogeneous and manifests with variable penetrance. The clinical outcome, prognosis, and correlation between PBGD genotype and phenotype were investigated in 143 Finnish and Russian AIP patients with 10 mutations (33G-->T, 97delA, InsAlu333, R149X, R167W, R173W, R173Q, R225G, R225X, 1073delA). Thirty-eight percent of the patients had experienced 1 or more acute attacks during their lives. The proportion of symptomatic patients has decreased dramatically from 49% to 17% among patients diagnosed before and after 1980, respectively. Patients with the R167W and R225G mutations showed lower penetrance (19% and 11%, respectively) and recurrence rate (33% and 0%, respectively) than patients with other mutations (range, 36%-67% and 0%-66%, respectively). Moreover, urinary excretions of porphyrins and their precursors were significantly lower in these patients (porphobilinogen [PBG], 47 +/- 10 vs. 163 +/- 21 micromol/L, p < 0.001; uroporphyrin, 130 +/- 40 vs. 942 +/- 183 nmol/d, p < 0.001). Erythrocyte PBGD activity did not correlate with PBG excretion in remission or with the clinical severity of the disease. Mutations R167W and R225G resulted in milder biochemical abnormalities and clinical symptoms indicating a milder form of AIP in these patients. In all AIP patients, normal PBG excretion predicted freedom from acute attacks. The risk of symptoms was highest for female patients with markedly increased PBG excretion (>100 micromol/L). Proper counseling contributed to the prevention of subsequent attacks in 60% of previously symptomatic and in 95% of previously symptom-free patients.


Subject(s)
Hydroxymethylbilane Synthase/urine , Porphyria, Acute Intermittent/genetics , Abdominal Pain/etiology , Adolescent , Adult , Analysis of Variance , Erythrocytes/metabolism , Female , Genotype , Humans , Hydroxymethylbilane Synthase/metabolism , Logistic Models , Male , Middle Aged , Phenotype , Porphyria, Acute Intermittent/complications , Porphyria, Acute Intermittent/metabolism , Precipitating Factors , Statistics, Nonparametric
7.
Gastroenterology ; 127(4): 1030-7, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15480979

ABSTRACT

BACKGROUND & AIMS: Peutz-Jeghers syndrome (PJS) is typically manifested as severe gastrointestinal polyposis. Polyps in PJS patients and in Lkb1(+/-) mice that model PJS polyposis are frequently characterized by elevated cyclooxygenase-2 (COX-2). This study was designed to determine whether COX-2 inhibition would reduce tumor burden in Lkb1(+/-) mice or Peutz-Jeghers patients. METHODS: Genetic interactions between Cox-2 and Lkb1 in polyp formation were analyzed in mice with combined deficiencies in these genes. Pharmacologic inhibition of COX-2 was achieved by supplementing the diet of Lkb1(+/-) mice with 1500 ppm celecoxib between 3.5-10 and 6.5-10 months. In PJS patients, COX-2 was inhibited with a daily dose of 2 x 200 mg celecoxib for 6 months. RESULTS: Total polyp burden in Lkb1(+/-) mice was significantly reduced in a Cox-2(+/-) (53%) and in a Cox-2(-/-) (54%) background. Celecoxib treatment initiating before polyposis (3.5-10 months) led to a dramatic reduction in tumor burden (86%) and was associated with decreased vascularity of the polyps. Late treatment (6.5-10 months) also led to a significant reduction in large polyps. In a pilot clinical study, a subset of PJS patients (2/6) responded favorably to celecoxib with reduced gastric polyposis. CONCLUSIONS: These data establish a role for COX-2 in promoting Peutz-Jeghers polyposis and suggest that COX-2 chemoprevention may prove beneficial in the treatment of PJS.


Subject(s)
Carrier Proteins , Cyclooxygenase Inhibitors/therapeutic use , Isoenzymes/antagonists & inhibitors , Peutz-Jeghers Syndrome/drug therapy , Protein Serine-Threonine Kinases , Proteins/genetics , Sulfonamides/therapeutic use , AMP-Activated Protein Kinases , Adaptor Proteins, Signal Transducing , Animals , Celecoxib , Cyclooxygenase 2 , Cyclooxygenase 2 Inhibitors , Disease Models, Animal , Humans , Intracellular Signaling Peptides and Proteins , Isoenzymes/genetics , Isoenzymes/physiology , Membrane Proteins , Mice , Mice, Inbred C57BL , Microcirculation/drug effects , Peutz-Jeghers Syndrome/enzymology , Peutz-Jeghers Syndrome/pathology , Prostaglandin-Endoperoxide Synthases/genetics , Prostaglandin-Endoperoxide Synthases/physiology , Pyrazoles
9.
EMBO J ; 23(4): 833-43, 2004 Feb 25.
Article in English | MEDLINE | ID: mdl-14976552

ABSTRACT

We recently demonstrated that the LKB1 tumour suppressor kinase, in complex with the pseudokinase STRAD and the scaffolding protein MO25, phosphorylates and activates AMP-activated protein kinase (AMPK). A total of 12 human kinases (NUAK1, NUAK2, BRSK1, BRSK2, QIK, QSK, SIK, MARK1, MARK2, MARK3, MARK4 and MELK) are related to AMPK. Here we demonstrate that LKB1 can phosphorylate the T-loop of all the members of this subfamily, apart from MELK, increasing their activity >50-fold. LKB1 catalytic activity and the presence of MO25 and STRAD are required for activation. Mutation of the T-loop Thr phosphorylated by LKB1 to Ala prevented activation, while mutation to glutamate produced active forms of many of the AMPK-related kinases. Activities of endogenous NUAK2, QIK, QSK, SIK, MARK1, MARK2/3 and MARK4 were markedly reduced in LKB1-deficient cells. Neither LKB1 activity nor that of AMPK-related kinases was stimulated by phenformin or AICAR, which activate AMPK. Our results show that LKB1 functions as a master upstream protein kinase, regulating AMPK-related kinases as well as AMPK. Between them, these kinases may mediate the physiological effects of LKB1, including its tumour suppressor function.


Subject(s)
Multienzyme Complexes/metabolism , Protein Serine-Threonine Kinases/metabolism , AMP-Activated Protein Kinase Kinases , AMP-Activated Protein Kinases , Adaptor Proteins, Vesicular Transport/genetics , Adaptor Proteins, Vesicular Transport/metabolism , Amino Acid Sequence , Cell Line , Enzyme Activation , Fibroblasts/metabolism , Humans , Molecular Sequence Data , Multienzyme Complexes/genetics , Mutation , Peptides/metabolism , Phosphorylation , Protein Binding , Protein Serine-Threonine Kinases/genetics , Protein Subunits/genetics , Protein Subunits/metabolism , Substrate Specificity
10.
J Biol ; 2(4): 28, 2003.
Article in English | MEDLINE | ID: mdl-14511394

ABSTRACT

BACKGROUND: The AMP-activated protein kinase (AMPK) cascade is a sensor of cellular energy charge that acts as a 'metabolic master switch' and inhibits cell proliferation. Activation requires phosphorylation of Thr172 of AMPK within the activation loop by upstream kinases (AMPKKs) that have not been identified. Recently, we identified three related protein kinases acting upstream of the yeast homolog of AMPK. Although they do not have obvious mammalian homologs, they are related to LKB1, a tumor suppressor that is mutated in the human Peutz-Jeghers cancer syndrome. We recently showed that LKB1 exists as a complex with two accessory subunits, STRAD alpha/beta and MO25 alpha/beta. RESULTS: We report the following observations. First, two AMPKK activities purified from rat liver contain LKB1, STRAD alpha and MO25 alpha, and can be immunoprecipitated using anti-LKB1 antibodies. Second, both endogenous and recombinant complexes of LKB1, STRAD alpha/beta and MO25 alpha/beta activate AMPK via phosphorylation of Thr172. Third, catalytically active LKB1, STRAD alpha or STRAD beta and MO25 alpha or MO25 beta are required for full activity. Fourth, the AMPK-activating drugs AICA riboside and phenformin do not activate AMPK in HeLa cells (which lack LKB1), but activation can be restored by stably expressing wild-type, but not catalytically inactive, LKB1. Fifth, AICA riboside and phenformin fail to activate AMPK in immortalized fibroblasts from LKB1-knockout mouse embryos. CONCLUSIONS: These results provide the first description of a physiological substrate for the LKB1 tumor suppressor and suggest that it functions as an upstream regulator of AMPK. Our findings indicate that the tumors in Peutz-Jeghers syndrome could result from deficient activation of AMPK as a consequence of LKB1 inactivation.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Adaptor Proteins, Vesicular Transport/metabolism , Multienzyme Complexes/metabolism , Protein Serine-Threonine Kinases/metabolism , AMP-Activated Protein Kinase Kinases , AMP-Activated Protein Kinases , Animals , Calcium-Binding Proteins , Catalytic Domain , Cell Line , Cell Line, Tumor , Cell-Free System , Embryo, Mammalian/cytology , Enzyme Activation/physiology , Fibroblasts/enzymology , Fibroblasts/metabolism , Genes, Tumor Suppressor , HeLa Cells/chemistry , HeLa Cells/enzymology , HeLa Cells/metabolism , HeLa Cells/pathology , Humans , Immunoprecipitation/methods , Kidney/chemistry , Kidney/cytology , Kidney/embryology , Kidney/enzymology , Liver/enzymology , Mice , Multienzyme Complexes/physiology , Multiprotein Complexes/metabolism , Multiprotein Complexes/physiology , Protein Kinases/chemistry , Protein Kinases/metabolism , Protein Serine-Threonine Kinases/biosynthesis , Protein Serine-Threonine Kinases/chemistry , Protein Serine-Threonine Kinases/deficiency , Protein Serine-Threonine Kinases/physiology , Protein Subunits/metabolism , Rats , Recombinant Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...